weekly_roundup
BioTechSign Daily Catalyst Roundup - November 08, 2026
Top BioTechSign catalyst names today: ITCI, BGNE, DCPH, SRPT, EYPT, RNA. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 8, 2026
Daily Biotech Catalyst Digest: November 08, 2026
ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| ITCI | Intra-Cellular Therapies | 100.0 | A | clinical activity 100% |
| BGNE | BeiGene Ltd | 100.0 | A | publication signal 100%, clinical activity 100% |
| DCPH | Deciphera Pharmaceuticals | 100.0 | A | clinical activity 100% |
| SRPT | Sarepta Therapeutics | 85.9 | A | clinical activity 100%, short interest 70%, dilution risk 48% |
| EYPT | EyePoint, Inc. | 84.8 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| RNA | Avidity Biosciences | 84.6 | A | publication signal 100%, clinical activity 100%, short interest 70% |
Recent Grade-Change Queue
- SLDB (Solid Biosciences) currently grades F with a 34.8/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 61%.
- PRQR (ProQR Therapeutics) currently grades F with a 23.7/100 catalyst score. Main inputs: publication signal 100%, dilution risk 46%, clinical activity 17%.
- PASG (Passage Bio) currently grades D with a 43.8/100 catalyst score. Main inputs: publication signal 100%, dilution risk 53%, short interest 10%.
- LYEL (Lyell Immunopharma) currently grades F with a 30.8/100 catalyst score. Main inputs: publication signal 100%, dilution risk 69%, short interest 50%.
- MBRX (Moleculin Biotech) currently grades F with a 21.7/100 catalyst score. Main inputs: dilution risk 92%, publication signal 80%, clinical activity 12%.
- IMV (IMV Inc) currently grades F with a 25.0/100 catalyst score. Main inputs: clinical activity 25%.
- GERN (Geron Corporation) currently grades D with a 45.0/100 catalyst score. Main inputs: publication signal 100%, dilution risk 50%, short interest 50%.
- GLUE (Monte Rosa Therapeutics) currently grades F with a 34.9/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 54%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.